Schrodinger SDGR Drug discovery — Total cost of revenues

Other product segments

Similar metrics at other companies

PTGXSingle Reportable — Cost Of Revenue Discovery Expenses Excluding Employee Expense Benefit And Allocation Share Based Compensation Expenses

$8.51M+127%

INCYTotal Cost of Revenue

$104.52M+42.8%

DNTHDiscovery Expenses — Research And Development Expense

$1.36M+51.4%

VCYTBiopharmaceutical and other revenue — Cost of Revenue

$8K-99.7%

DGXTotal Cost of Revenue

$1.95B+9.2%

KURADiscovery Stage Program — Research And Development Expense

$1.4M-33.0%

Questions, answered.

What is Schrodinger's drug discovery — total cost of revenues?

Schrodinger (SDGR) reported drug discovery — total cost of revenues of $16.74M in Q1 2026.

How has Schrodinger's drug discovery — total cost of revenues changed year-over-year?

Schrodinger's drug discovery — total cost of revenues increased by 12.3% year-over-year, from $14.91M to $16.74M.

What is the long-term trend for Schrodinger's drug discovery — total cost of revenues?

Over 4 years (2021 to 2025), Schrodinger's drug discovery — total cost of revenues has grown at a 8.0% compound annual growth rate (CAGR), from $45.82M to $62.25M.

What does drug discovery — total cost of revenues mean?

This metric captures the direct costs associated with delivering drug discovery services and maintaining research programs. Monitoring this helps evaluate the operational efficiency and cost-to-serve ratio of the drug discovery business.